Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Evaluating human papillomavirus vaccination programs.

Donovan B, Guy RJ.

Sex Transm Dis. 2013 Apr;40(4):290-1. doi: 10.1097/OLQ.0b013e318282d69b. No abstract available.

PMID:
23481536
2.

Controlling cervical cancer.

Bonati M, Garattini S.

Pharmacoeconomics. 2009;27(2):91-3. doi: 10.2165/00019053-200927020-00001. No abstract available.

PMID:
19254043
3.

Just implementation of human papillomavirus vaccination.

Malmqvist E, Natunen K, Lehtinen M, Helgesson G.

J Med Ethics. 2012 Apr;38(4):247-9. doi: 10.1136/medethics-2011-100090. Epub 2011 Dec 2.

PMID:
22138726
4.

[Swedish consensus on cervix cancer vaccination. Vaccination programs for eradication of HPV16/18 should be initiated in elementary schools].

Dillner J, Andrae B, Westermark B.

Lakartidningen. 2006 Nov 1-7;103(44):3377-9. Swedish. No abstract available.

PMID:
17152260
5.

Latin America. Price is the main barrier to wider use of papillomavirus vaccine.

Kaiser J.

Science. 2008 May 16;320(5878):860. doi: 10.1126/science.320.5878.860. No abstract available.

PMID:
18487164
6.

Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States.

Castle PE, Solomon D, Saslow D, Schiffman M.

Cancer. 2008 Nov 15;113(10 Suppl):3031-5. doi: 10.1002/cncr.23762.

7.

Healthcare spending in the case of a HPV16/18 population-wide vaccination programme.

Vanagas G, Padaiga Z.

Scand J Public Health. 2012 Jul;40(5):406-11. doi: 10.1177/1403494812455467. Epub 2012 Jul 20.

PMID:
22821227
8.

Challenges of implementing human papillomavirus (HPV) vaccination policy.

Raffle AE.

BMJ. 2007 Aug 25;335(7616):375-7. Review. No abstract available.

9.

Doubts on the appropriateness of universal human papillomavirus vaccination: is evidence on public health benefits already available?

Porta M, González B, Márquez S, Artazcoz L.

J Epidemiol Community Health. 2008 Aug;62(8):667. doi: 10.1136/jech.2007.073528. No abstract available.

PMID:
18621949
10.

HPV vaccination in France: uptake, costs and issues for the National Health Insurance.

Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H.

Vaccine. 2011 Apr 27;29(19):3610-6. doi: 10.1016/j.vaccine.2011.02.064. Epub 2011 Mar 5.

PMID:
21382486
11.

Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model.

Usher C, Tilson L, Olsen J, Jepsen M, Walsh C, Barry M.

Vaccine. 2008 Oct 16;26(44):5654-61. doi: 10.1016/j.vaccine.2008.07.098. Epub 2008 Aug 22.

PMID:
18723068
12.

The announcement by the GAVI Alliance Board to support human papillomavirus (HPV) vaccines in the world's poorest countries.

[No authors listed]

Vaccine. 2012 Nov 20;30 Suppl 4:xii. doi: 10.1016/S0264-410X(12)01440-5. No abstract available.

PMID:
23510773
13.

HPV vaccination.

Brotherton J.

Aust Fam Physician. 2007 Jun;36(6):391; author reply 391. No abstract available.

PMID:
17582901
14.

Human papillomavirus vaccination: expected impacts and unresolved issues.

Dempsey AF, Freed GL.

J Pediatr. 2008 Mar;152(3):305-9. doi: 10.1016/j.jpeds.2007.09.052. Review. No abstract available.

PMID:
18280831
15.

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.

Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.

BMC Med. 2012 Nov 13;10:136. doi: 10.1186/1741-7015-10-136.

16.

Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.

Khan K, Curtis CR, Ekwueme DU, Stokley S, Walker C, Roland K, Benard V, Saraiya M.

Cancer. 2008 Nov 15;113(10 Suppl):3004-12. doi: 10.1002/cncr.23765. Review.

17.

Monitoring the coverage and impact of human papillomavirus vaccine - report of WHO meeting, November 2009.

[No authors listed]

Wkly Epidemiol Rec. 2010 Jun 18;85(25):237-43. English, French. No abstract available.

18.

A brief history of economic evaluation for human papillomavirus vaccination policy.

Beutels P, Jit M.

Sex Health. 2010 Sep;7(3):352-8. doi: 10.1071/SH10018.

PMID:
20719227
19.

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.

Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.

Pharmacoeconomics. 2009;27(2):127-47. doi: 10.2165/00019053-200927020-00004. Review. Erratum in: Pharmacoeconomics. 2009;27(4):354.

PMID:
19254046
20.

Human papillomavirus vaccination--reasons for caution.

Haug CJ.

N Engl J Med. 2008 Aug 21;359(8):861-2. doi: 10.1056/NEJMe0804638. No abstract available.

Supplemental Content

Support Center